Satellite Bio Announces FDA Rare Pediatric Disease Designation for SB-101 for the Treatment of Urea Cycle Disorders (UCDs)
Satellite Biosciences, Inc. (Satellite Bio), a biotechnology company developing off-the-shelf liver therapies designed to restore liver function in patients with severe liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for SB-101 for the treatment of urea cycle disorders (UCDs).
